% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kass:909117,
      author       = {Kass, Bettina and Schemmert, Sarah and Zafiu, Christian and
                      Pils, Marlene and Bannach, Oliver and Kutzsche, Janine and
                      Bujnicki, Tuyen and Willbold, Dieter},
      title        = {{A}β oligomer concentration in mouse and human brain and
                      its drug-induced reduction ex vivo},
      journal      = {Cell reports / Medicine},
      volume       = {3},
      number       = {5},
      issn         = {2666-3791},
      address      = {Maryland Heights, MO},
      publisher    = {Elsevier},
      reportid     = {FZJ-2022-03017},
      pages        = {100630 -},
      year         = {2022},
      abstract     = {The elimination of amyloid beta (Aβ) oligomers is a
                      promising strategy for therapeutic drug development of
                      Alzheimer’s disease (AD). AD mouse models that develop Aβ
                      pathology have been used to demonstrate in vivo efficacy of
                      compounds that later failed in clinical development. Here,
                      we analyze the concentration and size distribution of Aβ
                      oligomers in different transgenic mouse models of AD and in
                      human brain samples by surface-based fluorescence intensity
                      distribution analysis (sFIDA), a highly sensitive method for
                      detecting and quantitating protein aggregates. We
                      demonstrate dose- and time-dependent oligomer elimination by
                      the compound RD2 in mouse and human AD brain homogenates as
                      sources of native Aβ oligomers. Such ex vivo target
                      engagement analyses with mouse- and human-brain-derived
                      oligomers have the potential to enhance the translational
                      value from pre-clinical proof-of-concept studies to clinical
                      trials.},
      cin          = {IBI-7},
      ddc          = {610},
      cid          = {I:(DE-Juel1)IBI-7-20200312},
      pnm          = {5244 - Information Processing in Neuronal Networks
                      (POF4-524)},
      pid          = {G:(DE-HGF)POF4-5244},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {35584626},
      UT           = {WOS:000830992600003},
      doi          = {10.1016/j.xcrm.2022.100630},
      url          = {https://juser.fz-juelich.de/record/909117},
}